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Background: Studies from both developed and developing countries have demonstrated a considerable
fluctuation in the average cost of TB treatment. The objective of this study was to analyze the medical resource
utilization among new smear positive pulmonary tuberculosis patients. We also estimated the cost of tuberculosis
treatment from the provider and patient perspectives, and identified the significant cost driving factors.
Methods: All new smear positive pulmonary tuberculosis patients who were registered at the chest clinic of the
Penang General Hospital, between March 2010 and February 2011, were invited to participate in the study. Provider
sector costs were estimated using bottom-up, micro-costing technique. For the calculation of costs from the
patients’ perspective, all eligible patients who agreed to participate in the study were interviewed after the intensive
phase and subsequently at the end of the treatment by a trained nurse. PASW was used to analyze the data
(Predictive Analysis SoftWare, version 19.0, Armonk, NY: IBM Corp.).
Results: During the study period, 226 patients completed the treatment. However, complete costing data were
available for 212 patients. The most highly utilized resources were chest X-ray followed by sputum smear
examination. Only a smaller proportion of the patients were hospitalized. The average provider sector cost was MYR
992.34 (i.e., USD 325.35 per patient) whereby the average patient sector cost was MYR 1225.80 (i.e., USD 401.90 per
patient). The average patient sector cost of our study population accounted for 5.7% of their annual family income.
In multiple linear regression analysis, prolonged treatment duration (i.e., > 6 months) was the only predictor of
higher provider sector costs whereby higher patient sector costs were determined by greater household income
and persistent cough at the end of the intensive phase of the treatment.
Conclusion: In relation to average provider sector cost, our estimates are substantially higher than the budget
allocated by the Ministry of Health for the treatment of a tuberculosis case in Malaysia. The expenses borne by the
patients and their families on the treatment of the current episode of tuberculosis were not catastrophic for them.
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Prevalence and incidence rates are the most common
indicators to weigh the burden of tuberculosis (TB) and
highlight the gravity of the epidemic. However, these
pointers may fail to explain the trends in the societal
and economic burden of the disease [1]. Therefore, it
is crucial not only to highlight the importance of an
increase in the incidence rates, but also to address the
structural and economic barriers which may be acting
together to fuel the epidemics [2-4].
The economic impact of TB is often measured in terms
of direct and indirect costs to the public health care ser-
vices. These include the cost of medicines, employees and
other health care facilities [5]. Assessing the utilization of
health care resources at governmental level is always im-
portant to provide long-term planning in a highly dynamic
health care system [6]. Furthermore, cost estimates are in-
creasingly required by insurance companies, government
payers and others groups which are conscious to their
limited research and treatment budget.
In order to fully understand the impacts of TB on the
well-being of the members of a society, there is a need to
take into account the costs incurred by the patients, their
families and communities [7,8]. Unfortunately, these are
occasionally overlooked over the expenses of governmen-
tal agencies such as departments of health [5]. As such,
many of the government budgets were allocated in a way
which did not minimize the burden of the disease [4,7].
Studies from developing countries have demonstrated
that an average cost for the treatment of a drug suscep-
tible TB case ranged from USD 94.00 to USD 2058.00
[4,8-14]. Similarly, studies from developed countries
have shown a considerable fluctuation in the average
cost of TB treatment [6,15]. The high variation of the cost
of TB treatment is caused by the different health care sys-
tems, perspectives (i.e., provider and patient), cost compo-
nents, and methods of calculation and data collection
used by the respective researchers. This means that this
information is neither transferable nor any of the implica-
tions arising from these studies can be applied to other
health care settings [16].
As a country that is seeing resurgence of TB incidence,
understanding of the burden of such disease in the local
setting is critical for its successful management. Therefore,
the objective of this study was to analyze the medical
resource utilization among new smear positive pulmonary
tuberculosis (PTB) patients. We also estimated the cost of
TB treatment from the provider and patient perspectives,
and identified the significant cost driving factors.
Methods
Study setting
The study was conducted at the chest clinic of the Penang
General Hospital (PGH), which is the first health carefacility in Malaysia since 1961. The chest clinic of PGH
has eight to nine full-time medical doctors, including
three chest consultants. Besides this, the chest clinic
has paramedic staff to provide quality care to the pa-
tients. The chest clinic has well equipped TB diagnostic
laboratory where the specimens of suspected and exist-
ing TB patients are investigated using sputum smear
examination, culture, nucleic acid amplification tests and
drug sensitivity testing (DST). The radiology and path-
ology departments of the PGH also provide routine
investigation services to TB patients.
Confirmed TB patients are advised to take their medi-
cation either at the chest clinic or at a primary health
care unit. In general, patients are advised to take their
daily medicines under the direct observation of a staff
nurse at the chest clinic or a primary health care unit.
However, some patients are allowed weekly packing of
the daily dose. Weekly packing of the daily dose is only
available at the chest clinic. The patients who continue
their daily treatment at a primary health care unit are
advised to visit the chest clinic (every 2 weeks during
the intensive phase (IP) and every month during the
continuation phase (CP) of the treatment) for routine
investigation. Patients who default from their treatment
for five consecutive days are traced by a team of staff
comprising of a TB-coordinator, a staff nurse and an
attendant [17,18].
Study design and population
A prospective, incidence-based study design was employed
[19,20]. The population in this study consisted of all
new smear positive PTB patients who were diagnosed
and successfully completed their treatment at the study
site between March 2010 and February 2011. The costs
attributed to the treatment of TB were estimated from
the provider and patient perspectives (Figure 1). Pro-
vider costs were estimated using bottom-up, micro-
costing technique [21], whereby patient sector costs
were estimated by an interviewed-administered question-
naire [4,22]. The patients who defaulted, transferred-out
or died during the treatment were excluded from the
study [7,12].
Data collection and costing
The medical records of the patients were reviewed for
the information on their socio-demographic, clinical and
treatment-related characteristics, and resource utilization
pattern. To estimate the patient sector costs, a trained
nurse invited all eligible patients (i.e., a new case of smear
positive PTB) to participate in the study. The nurse
explained the purpose of the study and assured the
consenting patients about the confidentiality of the in-
formation provided. All consented patients were inter-






















Figure 1 Outline of the cost analysis.
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interviewer-administered questionnaire [4,12,15,22]. The
respondents who were either unwilling to be interviewed
on the second occasion or those who defaulted, died or
transferred-out were excluded from the study [12]. Details
about the average household monthly income and loss of
time due to illness were provided by the patients during
the interviews.
Provider sector costs
The total provider sector cost was the sum of outpatient
clinic costs (i.e., the sum of human resource cost, capital
cost, electricity cost and consumables cost), hospitalization
costs, chest X-ray costs (i.e., the sum of human resource
cost, capital cost, electricity cost and consumables cost
[23,24]), laboratory services costs (i.e., the sum of human
resource cost, capital cost, electricity cost and consum-
ables cost) and medicines costs of all patients included
in the study. The average provider sector cost was ob-
tained by dividing the total provider cost by the number
of successfully treated patients.
To estimate the human resource cost for each service,
a time motion study on activity-based-costing (ABC)
approach was used. Interviews with the key personnel
at the chest clinic and other departments were con-
ducted to identify the principal activities of each service
provided to the enrolled patients. This was followed byrecording the time taken to complete each activity using
a stopwatch. The duration was captured 15 times each
for three alternate days and summarized as the mean
time (minutes) for each activity. The personnel time
cost for each of the employees involved was calculated
according to the pay scale of the Federal Civil Services
Officers under the System of Remuneration Malaysia
[25]. Prior to the calculation, these salaries were con-
verted into the salary per minute (MYR/min) by assum-
ing a daily working time of 8 hours and a monthly
working time of 20 days [23,24]. The cost of each em-
ployee per single activity was obtained by multiplying
the mean time (minutes) spent by that employee doing
a specific activity by his/her salary per minute. Finally,
the total human resource cost per service was the sum
of human resource cost of all activities involved in that
specific service [23,24].
The costs of the equipment and furniture were
obtained from the procurement section of each depart-
ment. The costs of the building were calculated by
multiplying the area size of the service with the unit
cost of public building (MYR 85/ft2) [24]. The useful life
was assumed to be 5 years for clinical equipment and
30 years for the building [26]. Moreover, straight-line
deprecation with a discount rate of 3% was used. At the
end of the asset’s useful life, the resale value was consid-
ered to be 10% of the initial costs [21]. The equivalent
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following equations:
Asset Resale Value ¼ Asset Cost  0:1
Present Value ¼ Resale Value  Discount Rate
Net Present Value of the Asset Cost
¼ Asset Cost ‐ Present Value
Equivalent Annual Cost
¼ Net Present Value of the Asset Cost
Annuity Factor½ 
The unit asset cost was obtained by dividing the
equivalent annual cost of each asset by the total number
of patients exposed to that service in one year. The total
capital cost was the sum of unit costs of all the assets
involved in the specific service.
Annual electric power consumption (kW/h) for each
of clinical equipment was calculated separately and
then multiplied by the unit price of one kW/h (MYR
0.312/kWh) [27]. The resultant annual electricity cost
for each of the equipment was then divided by the number
of patients exposed to the service (in one year) to obtain
the cost per service. The total electricity cost was the sum
of unit costs of all equipment involved in the specific
service. Likewise, exactly the same method was adopted
in estimating the electricity costs of other electrical
appliances (e.g., fans, air conditioners, fridge, etc.).
Evidence of consumable expenditure was already avail-
able for the majority of the laboratory tests conducted in
the various sections of the pathology department. For the
remaining tests/services, inclusive information about
the utilization of consumables was collected by following
the complete activity. In this case, the unit cost of each
consumable was obtained from the procurement section
of the relevant department. For each test/service, the total
cost of consumables was the sum of unit costs of all the
consumables used in that specific test/service.
The unit price of the medicines for the total duration
of therapy was dependent on the number and quantity
of TB drugs and the duration of therapy. The drug costs
were obtained from the procurement section of the
pharmacy department of the PGH.
The total cost of hospital admission was obtained by
multiplying the length of hospital stay (days) by the daily
hospitalization cost of MYR 285.00 [28].
Patient sector costs
The total patient sector cost was the sum of out-of-
pocket expenditures and productivity costs of the pa-
tients enrolled in this study. The total patient sector cost
was divided by the total number of enrolled patients to
arrive at an average patient sector cost.Out-of-pocket expenditures included prescribed or
over-the-counter non-TB medicine (e.g., paracetamol, vi-
tamins, etc.) costs, private medical consultation fees, the
amount spent on private laboratory and imaging services
(e.g., chest X-rays, liver function tests, etc.), transporta-
tion costs (from home to the chest clinic or a primary
health care unit and parking/toll charges), special food
costs and other costs (i.e., extra telephone bills, hotel
stay, etc.). Out-of-pocket expenditures were calculated
for the IP and CP of the treatment.
Productivity costs were calculated using the human
capital approach as loss of time (days) due to illness.
These costs were calculated by using the following
equation [22]:
Productivity Costs ¼ Average Monthly Income of the Patient
20
 
 Loss of Time daysð Þ
Where;
20 = number of working days in a month
The proportion of the average patient sector cost in
relation to the annual family income of the patients (af-
fordability assessment) was calculated by using following
equation [7,22]:
Affordibility %ð Þ ¼ Average Patients Sector Cost per Patient
Average Monthly Household Income  12ð Þ
 100
Where;
12 = number of months in a year
Health expenditures exceeding 10% of family income
were considered catastrophic [4,29].
Definition of terms
Prolonged treatment duration
The total duration of TB treatment longer than 6 months
represented prolonged treatment duration [30].
High-grade sputum
Sputum was graded according to the number of acid-
fast bacilli (AFB) visible at the time of sputum smear
microscopy. To simplify the grading categories, four grades
(i.e., scanty positive, 1+, 2+ and 3+) were combined to
two categories. Scanty positive and 1+ represented low-
grade sputum, whereby 2+ and 3+ denoted high-grade
sputum [31].
Statistical analysis
The data was tabulated using Microsoft Excel (2010) and
subsequently analyzed by using the PASW (Predictive
Analysis SoftWare, version 19.0, Armonk, NY: IBM
Corp.). All costs were reported as mean and median.
Kolmogorov-Smirnov test was used to test the normal-
ity of the distribution of cost data. Costs were found to
Table 1 Socio-demographic characteristics of the patients






































*Indonesian (n = 1), Myanmar (n = 1).
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analysis (log-transformed costs) was used to examine
the possible association between cost and selected
socio-demographic and clinical variables. Only the sta-
tistically significant variables in the univariate analysis
were entered into the multiple linear regression analysis
to predict the final independent cost driving factors.
The significance of the statistical tests was taken at a
p-value of <0.05.
All costs were reported in Malaysian Ringgit (MYR).
However, some costs (i.e., the average provider cost, the
average patient cost and the total average cost of TB)
were also presented in the United States Dollars (USD)
for the ease of comparisons with published studies (con-
version rate of USD 1 =MYR 3.05).
Ethical approval
The study was approved by the Medical Research Ethics
Committee (MERC), Ministry of Health, Malaysia (MERC
reference: dim. KKM/NIHSEC/08/08/04P10-69).
Results
During the treatment, 226 patients completed their treat-
ment. However, complete costing data were available for
212 patients. The average household income of the study
participants was MYR 1789.90 per month. The average
duration of TB treatment was 8.18 (SD = 1.64) months
(249 days). Tables 1 and 2 provide details about the socio-
demographic and clinical characteristics of the patients,
respectively.
Provider sector costs
Table 3 describes a complete picture of TB-related medical
resource utilization pattern.
The total provider sector cost for the successful treat-
ment of 212 new smear positive PTB patients was MYR
210376.93. Outpatient clinic costs constituted the high-
est proportion (38.7%) of the total cost followed by the
medicine costs (21.6%). The average provider sector cost
was MYR 992.34 (median =MYR 891.55) (USD 325.35
per patient). Table 4 provides details about the provider
sector cost.
Patient sector costs
Out of 212 eligible patients, 198 agreed to participate in
the study. Among the consented patients, six (9.4%)
dropped-out from the second interview. Therefore, the us-
able sample size for patient sector costs was 192 patients.
Most of the out-of-pocket expenditures were made on
transportation (40%) and special food (29.5%). The total
out-of-pocket expenditures per patient were MYR 439.42
(median =MYR 345.00) (Table 5).
On an average, each patient lost 10 days (median = 8 days;
range = 3–29 days) of normal productivity during thecomplete course of treatment. The total productivity
cost for all patients (N = 192) was MYR 150,985.40,
while the average productivity cost was MYR 786.38
(median =MYR 515.75).
The total patient sector cost (N = 192), derived as the
sum of out-of-pocket expenditures and productivity costs,
was MYR 235,353.40 (Table 6). The average patient sector
Table 2 Clinical characteristics of the patients
Characteristics Patients n (%)
Form of TB
S+ PTB* 205 (96.7)







Persistent cough at the end of the intensive phase
Yes 52 (24.5)
No 160 (75.5)











Prolonged treatment duration (>6 months)
Yes 157 (74.1)
No 55 (25.9)
*Smear positive pulmonary tuberculosis; †Extrapulmonary tuberculosis;
‡Percentages calculated on the basis of N = 212.







Scheduled consultation visits 1683 (100) 7.94 (8)
Visits for medicine (DOT* room
visits)
30931 (100) 145.9 (160)
Consultations with the specialist
(head of the department)
62 (27.4) 0.99 (1)
Consultations with the specialist 116 (45.3) 1.21 (1)
Consultations with the medical
officer
1561 (100) 3.56 (3)
TB coordinator 848 (100) 4 (4)
Counter clerk and attendant 212 (100) 1 (1)
Lab. investigation attendant 1107 (100) 2.65 (3)
Hospitalization 77 (11.8) 0.36 (0)
Chest X-ray 1233 (100) 5.82 (6)
Laboratory tests
Bacteriological tests
Sputum smear 667 (100) 3.15 (3)
Culture 165 (71.7) 0.78 (1)
Polymerase chain reaction 152 (69.3) 0.72 (1)
Drug sensitivity testing 150 (68.4) 0.71 (1)
Non-specific tests
Biochemical 839 (99.5) 3.96 (3)
Hematological 421 (93.9) 1.99 (2)
Serological 279 (86.8) 1.32 (1)
*DOT: Directly Observed Treatment.
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401.90 per patient). The average patient sector cost of our
study population accounted for 5.7% of their annual family
income.
Total average cost of tuberculosis treatment
The total average cost of TB treatment (provider and
patient perspective) was MYR 2,218.14 (USD 727.24
per patient). Table 7 shows that the amount paid by the
patient constituted 55.3% of the total average cost.
Provider and patient sector cost driving factors
Table 8 describes the provider and patient sector cost
driving factors using a multiple linear regression analysis.
Provider costs were higher among the patients with treat-
ment duration more than 6 months (p = 0.002). However,
lower provider costs were associated with twice-weekly
dosing schedule (p <.0005). Similarly, higher patient costs
were associated with greater household monthly income(p <.0005) and persistent cough at the end of the IP of the
treatment (p = 0.004). However, patient costs were signifi-
cantly lower among the unemployed patients (p = 0.003).
Discussion
Assessing the utilization of health care resources is critical
for long-term planning in the changing health care system
and evaluating cost-effective strategies [6]. Our findings
showed 145.9 directly observed treatment (DOT) visits
per patient. In contrast, a Haitian study reported 75 DOT
visits per patient [32]. Along the same lines, studies from
Tanzania and Tajikistan mentioned fewer than 80 DOT
visits per patient [11,12]. Nonetheless, these differences in
DOT visits might be associated with difference in treat-
ment strategies (i.e., daily dose vs. twice-weekly dose,
DOT at clinic vs. weekly packing of the daily dose)
employed at these settings. Alternatively, variations in the
average treatment duration might be another reason for
such differences.
In this study, the proportion of hospitalized patients
was quite low (11.8%). Likewise, a study from Zambia
reported only 6% hospitalization rate among TB suspects
Table 4 Total provider sector cost









Human resource 57004.58 (69.9)
Scheduled consultation visits 7668.14 6149.29 13817.43
Visits for medication (DOT* room visits) 8331.40 15485.47 23816.87
Consultations with the specialist 1008.60 33.62 1042.22
Consultations with the specialist (head of the department) 887.40 - 887.40
Consultations with the medical officer 6795.73 6670.71 13466.44
TB coordinator 1539.12 1539.12 3078.24
Counter clerk and attendant 165.36 - 165.36
Lab. investigation attendant 508.20 222.42 730.62
Capital 3137.80 5832.09 8969.89 (11.0)
Electricity 5085.40 9452.01 14537.41 (17.8)
Consumables 946.28 43.53 989.81 (1.2)
Sub-total 81501.69 (38.7)
Hospitalization 22022.00 - 22022.00 (10.5) 103.88
Chest X-ray 4480.45 2486.00 6966.45 (3.3) 32.86
Bacteriological tests
Sputum smear 2155.71 492.28 2647.99 (6.7)
Culture 1323.30 - 1323.30 (3.4)
Polymerase chain reaction 15493.36 - 15493.36 (39.5)
Drug sensitivity testing 19791.00 - 19791.00 (50.4)
Sub-total 39255.65 (18.7) 185.17
Non-specific laboratory tests 12946.43 2139.70 15086.13 (7.2) 71.16
Medicines 25069.95 20475.06 45545.01 (21.6) 214.83
Total Cost 139355.63 71021.30 210376.93 (100) 992.34
*DOT: Directly Observed Treatment.
Note: All costs in Malaysian Ringgit. Bold numbers reflect sub-total of cost components, grand total cost and cost per patient.
Table 5 Total out-of-pocket expenditures
Cost element Cost during intensive phase Cost during continuation phase Total cost (% of total cost) Cost per patient
Consultation fees 4184.00 2771.00 6955.00 (8.2) 36.22
Chest X-ray 1324.00 785.00 2109.00 (2.5) 10.98
Non-TB medicines 3662.00 85.00 3747.00 (4.4) 19.52
Laboratory tests 1956.00 2331.00 4287.00 (5.1) 22.33
Traditional medicine 3653.00 2614.00 6267.00 (7.4) 32.64
Transportation 15790.00 17939.00 33729.00 (40.0) 175.67
Special food 15533.00 9319.00 24852.00 (29.5) 129.44
Other 480.00 1942.00 2422.00 (2.9) 12.61
Total out-of-pocket expenditures 84368.00 (100) 439.42
Note: All costs in Malaysian Ringgit.
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Table 6 Total patient sector cost
Cost element Total patient cost (%) Cost per patient
Out-of-pocket expenditures 84368 (35.9) 439.42
Productivity costs 150985.40 (64.1) 786.38
Total cost 235353.40 (100) 1225.80
Note: All costs in Malaysian Ringgit.
Table 8 Final provider and patient sector cost driving
factors: multiple linear regression analysis with log-
transformed costs
Independent variables B S.E p-value
Provider sector*
Indian ethnicity .114 0.032 .071
High-grade sputum .122 0.021 .057
Lung cavities .099 0.020 .126
Twice-weekly dose -.267 0.022 <.0005
Prolonged treatment duration .207 0.022 .002
Patient sector†
Age‡ -.084 0.002 .219
Widow/divorced -.001 0.070 .994
University education .029 0.074 .685
Unemployment -.195 0.055 .003
Household income‡ .515 0.001 <.0005
Persistent cough at the end of intensive phase .178 0.048 .004
*Model summary: R2 = .286, p <.0005; †Model summary: R2 = .419, p <.0005;
‡Denotes continuous variable.
Note: Only statistically significant variables in univariate analysis were entered
in multiple linear regression analysis and are shown in the table.
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diagnosis of TB [10]. On the other hand, studies from
the Netherlands, Haiti, Tajikistan and India reported 25–
75% hospitalization rates among TB patients [12,22,32,33].
In our study, lower number of hospitalizations was a con-
sequence of the local health care policy of not admitting
new smear positive PTB patients in the hospital wards.
Appropriate treatment of smear positive index cases could
render most of them non-infectious, usually within
2 weeks. Additionally, the infectivity could be signifi-
cantly decreased within 2 days of standard TB therapy.
Hence, hospitalization should only be reserved for severely
ill TB patients (e.g., severe cough and high fevers) and for
those who are unable to take care of themselves.
In our study, all enrolled patients were investigated
and monitored through chest roentgenogram. The average
number of chest X-ray films per patient was 5.82. Studies
from Thailand and Lusaka reported an average of two
chest X-ray films per patient [4,34]. In our study, most of
the patients did not produce sputum for bacteriology after
1–2 months of TB treatment. As a result, the clinicians
were unable to monitor the treatment progress through
smear microscopy. Consequently, they had to monitor the
treatment progress through frequent chest X-rays. How-
ever, according to World Health Organization (WHO), it
is pointless, unreliable and wasteful of resources to moni-
tor the patient through the use of chest X-rays [30].
Cost and cost-effectiveness studies from Tanzania,
Uganda and South Africa emphasized the importance of
implementing community-based TB care [9-11]. A sys-
tematic review which compared self-administered ther-
apy with DOT concluded that DOT did not improve the
outcomes [35]. On the contrary, other review articles
suggested DOT to be associated with higher treatment
success rates [36,37]. In line with the findings of above-
cited studies and owing to higher outpatient clinic costs
in our study (i.e., 38.7% of the total provider sector cost),Table 7 Cost of tuberculosis treatment per patient
treated
Perspective Cost per patient % from total cost
Provider 992.34 44.7
Patient 1225.80 55.3
Total cost 2218.14 100
Note: All costs in Malaysian Ringgit.community involvement appears to be an attractive eco-
nomic option. A network of strong community-based
TB care may be attained through active involvement of
NGOs (non-governmental organizations) and treatment
supporters. Cured TB patients can be the best treatment
supporters, as can friends, family members, neighbors,
religious leaders and holistic practitioners [30,38]. We
also believe that DOT room visits and associated costs
could be reduced by adopting WHO recommended
three times a week therapy during the CP of the treat-
ment. Alternatively, weekly packing of the daily dose
could be an option to reduce the DOT room visit costs.
In this study, the cost of bacteriological tests constituted
18.7% of the total provider cost. A notable proportion
(89.9%) of this cost was shared by DST and polymerase
chain reaction (PCR). As per the recommendations of
WHO, DST should be performed in settings where coun-
try data (or WHO estimates) suggests multidrug-resistant
tuberculosis (MDR-TB) in more than 3% of new patients.
WHO also recommends performing culture and DST in
new TB patients (from areas with <3% MDR-TB rates) if
they are still positive for AFB on direct smears at the end
of the third month of TB treatment. According to a recent
TB country profile, the percentage of TB cases with MDR-
TB was only 0.1% in Malaysia [39]. Using these facts and
recommendations by WHO [30], a strategy of limiting the
use of DST and PCR for the re-treatment cases or for
those who are still smear positive at the end of the third
month of treatment could significantly reduce the pro-
vider cost in the local settings (Note: unit cost of DST =
MYR 131.94, unit cost of PCR = MYR 101.93). Earlier
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countries did not prefer these tests for new smear positive
PTB patients owing to higher costs [10,33,34].
The cost of TB medicines was the second highest cost
component after the outpatient clinic costs in that it
constituted 21.6% of the total provider sector cost. These
results are somewhat comparable to the findings of similar
studies published elsewhere [10,13]. However, a few stud-
ies from developing and developed countries showed that
the cost of TB medicines ranged from 4.7–63.8% of the
total cost of TB management [6,9-11,14,32]. Differences in
cost accounting methods, characteristics of study popula-
tion and variability in the unit cost of TB medicines are
some of the factors that could explain inconsistency in the
findings of various studies.
With regard to patient sector costs, out-of-pocket expen-
ditures constituted 35.9% of the total cost to the patients.
Among these out-of-pocket payments, transportation and
special food costs created the highest impact. Consistent
with our findings, studies from the Netherlands, Tajikistan,
Yemen, India and Thailand reported higher transportation
and special food costs [7,12,14,22,33]. As such, weekly
packing of TB drugs in the presence of suitable treatment
supporters could be an option to reduce the out-of-pocket
costs to the patients.
In this study, on an average, each patient lost 10 days
of normal productivity. Conversely, TB patients lost an
average of 135 working days in Tajikistan [12]. Similarly,
average work time loss in TB patients was 81 days in
the Netherlands [22]. Differences in the work time loss
between these studies might be attributed to the policy
of compulsory hospitalization of smear positive PTB
patients in some countries. In fact, a greater proportion
of the patients were hospitalized in above-cited studies
from Tajikistan and the Netherlands.
The average patient sector cost of our study population
accounted for 5.7% of their annual family income. This is
an indication that these expenses were not catastrophic
for them. However, these costs could be a considerable
portion of their disposable income after payment of all
monthly fixed costs such as rentals, monthly installments,
bills (i.e., electricity, water and gas) and insurances. A
study from Thailand reported that expenses borne by TB
patients ranged from 5.1–20.3% based on different income
groups [7]. However, existing literature reported that
the costs borne by TB patients could be as high as 75%
of their annual household income [22]. The differences
among the findings of various studies might be the con-
sequence of differences in the socioeconomic status of
study participants. Another possibility could be differences
in the accessibility of health care services irrespective of
ability to pay. In Malaysia, TB patients are neither charged
for diagnostic services, nor for TB medicines. Further-
more, TB patients are given top priority in terms ofconsultations with the medical practitioners. In addition,
TB patients are further facilitated by providing routine
therapy at the primary health care units. All these mea-
sures are taken to substantially reduce the patient sector
costs to an extent that these are not catastrophic for them
and/or their families. The results of this study add weight
to the appropriateness of all measures taken to alleviate
the financial burden of the disease on patients.
According to our estimates, the total average cost of
treatment for a new smear positive PTB patient was MYR
2,218.14 (USD 727.26). The average patient cost was
slightly higher (54.3%) than the provider cost. Recently, a
study from Western Asia showed that the average cost of
treating a PTB patient was USD 142.40, in which patient
costs constituted 76.1% of the total cost [14]. In 2005, a
Tanzania study reported that on an average USD 145.00
were required to treat an episode of TB, whereby the
provider costs constituted 70.3% of the total cost [11].
Another study from Africa showed that an average of
USD 703.00 was required to treat a PTB patient [10]. In
summary, the total average cost of TB treatment varied
noticeably among various studies as did the distribution
between the health services and the patients.
In multiple linear regression analysis, higher provider
costs were associated with longer treatment duration.
This is an indication that the patients in whom the treat-
ment was prolonged had utilized the health care resources
for a relatively longer period of time. In contrast, twice-
weekly dosing schedule during the CP of the treatment
was the only factor inversely related to higher provider
costs. A possible explanation for this association could be
relatively lower utilization of DOT room for the collection
of TB medicines.
Highly educated individuals are socially advantaged,
and thus are more likely to seek frequent medical care at
private health facilities. In turn, they have to bear more
out-of-pocket expenditures [40]. Similarly, patients with
persistent signs and symptoms are more likely to spend
on their health in the form of consultations with private
medical practitioners and/or use of complementary and
alternative medicines. In accordance with these argu-
ments, we also found a similar relationship between
patient-related costs and our study variables.
Our study has three limitations. First, in this study, we
only included smear positive PTB patients. The cost of
retreatment cases and those with MDR-TB is sometimes
substantial [6]. Therefore, our results could not be gen-
eralized for all forms of TB patients. However, from the
public health perspective, smear positive PTB patients
are the most important group of TB patients, and these
are the most common group of patients used to evaluate
the performance of National Tuberculosis Program. Sec-
ond, costs reported by the patients could have been biased
because of patients’ failure to recall certain out-of-pocket
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recall bias could lead to underestimation or to some
extent overestimation of patient sector costs. However, we
helped the patients in their recall work using a calendar of
locally important events. In the event of reporting unex-
pectedly high or low costs, patients were asked again to
confirm the accuracy of information. We strongly believe
that these measures could have significantly reduced the
recall bias, and our cost estimates are reliable. Finally, we
conducted our study in a public sector hospital where TB
patients are treated free of cost. Therefore, cost structure
could be substantially different for the patients who seek
care in the private health care sector where they are
charged based on the type and frequency of service
utilized.
Conclusion
Our findings could be used to predict medical utilization
for the diagnosis and treatment of TB in patients seeking
care in a public sector hospital. In relation to average pro-
vider sector cost, our estimates are substantially higher
than the budget allocated by the Ministry of Health for
the treatment of a TB case in Malaysia (i.e., USD 325.35
vs. USD 225.00). We also found that TB diagnosis and
treatment did not pose a significant economic burden on
the patients and their families. Community-based DOT,
limited use of DST and PCR, and special attention to the
cost driving factors are some of the options to reduce cost
of TB treatment. However, future studies are required to
warrant these statements.
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